CCXI ChemoCentryx, Inc.

7.35
-0.21  -2.78%
Previous Close 7.56
Open 7.57
Price To book 6.65
Market Cap 351.37M
Shares 47,805,000
Volume 140,229
Short Ratio 5.90
Av. Daily Volume 269,692

SEC filingsSee all SEC filings

  1. 8-K - Current report 162065837
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981173
  3. 8-K - Current report 161978521
  4. 8-K - Current report 161950417
  5. 8-K - Current report 161943920

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Partner required to continue with Phase 3 program
Vercirnon CCX282
Crohn’s disease
Phase 2 top-line data released Dec 12 2014. Partner required for further development.
CCX140
Diabetic nephropathy
Phase 1b early response data released September 1, 2016. Initial PFS data released January 20, 2017.
CCX872
Non-resectable pancreatic cancer
Phase 2 data presented at ASN Kidney Week - November 17, 10:00 to 2:00 p.m. CT
CCX168
Atypical Hemolytic Uremic Syndrome (aHUS)
Phase 3 initiated December 2016.
CCX168
Associated vasculitis (AAV)

Latest News

  1. 3:34 pm ChemoCentryx presents from a continuing open-label, single-arm Phase Ib clinical trial of CCX872 at ASCO 2017; plans to further investigate CCX872 in combination with a checkpoint inhibitor.
  2. ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
  3. ChemoCentryx, Inc. (Nasdaq: CCXI) to Ring The Nasdaq Stock Market Closing Bell Remotely from the Nasdaq Entrepreneurial Center in San Francisco
  4. ChemoCentryx, Inc. breached its 50 day moving average in a Bullish Manner : CCXI-US : January 19, 2017
  5. ChemoCentryx Provides Corporate Update Including Development Strategy for Lead Programs in Rare Renal Diseases
  6. ChemoCentryx to Present at the 35th Annual J.P. Morgan Healthcare Conference
  7. ChemoCentryx, Inc. – Value Analysis (NASDAQ:CCXI) : January 3, 2017
  8. ChemoCentryx, Inc. breached its 50 day moving average in a Bearish Manner : CCXI-US : January 2, 2017
  9. Vifor Pharma and ChemoCentryx announce expansion of Kidney Health Alliance to include CCX140 to treat renal diseases01
  10. ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases
  11. CHEMOCENTRYX, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
  12. Vifor Pharma and ChemoCentryx Announce Expansion of Kidney Health Alliance to Include CCX140 to Treat Renal Diseases
  13. Is ChemoCentryx Inc (CCXI) A Stock Worth Buying?
  14. Everyday Health Inc (EVDY), ANSYS, Inc. (ANSS), More: Why You Should Pay Attention To These Stocks
  15. CHEMOCENTRYX, INC. Financials
  16. CHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report
  17. Edited Transcript of CCXI earnings conference call or presentation 7-Nov-16 10:00pm GMT
  18. CHEMOCENTRYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
  19. ChemoCentryx Reports Third Quarter 2016 Financial Results and Provides Corporate Update
  20. ChemoCentryx to Hold Third Quarter 2016 Financial Results Conference Call on Monday, November 7, 2016

SEC Filings

  1. 8-K - Current report 162065837
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 161981173
  3. 8-K - Current report 161978521
  4. 8-K - Current report 161950417
  5. 8-K - Current report 161943920
  6. CT ORDER - Confidential treatment order 161889210
  7. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 161851979
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 161817215
  9. 8-K - Current report 161814566
  10. 8-K - Current report 161681012